Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.71 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063955 | 0.89 | EGFR (0.76) | EGFRCDK1CA1CA2CA9 | |
| SCHEMBL13675042 | 0.89 | EGFR (0.68) | EGFRCDK1SOS1 | |
| SCHEMBL13672686 | 0.83 | EGFR (1.00) | EGFRCDK1 | |
| SCHEMBL5069434 | 0.81 | EGFR (1.00) | EGFRCDK1CA1CA2CA9 | |
| SCHEMBL13672682 | 0.80 | EGFR (1.00) | EGFRCDK1CA1CA2CA9 | |
| SCHEMBL13675240 | 0.80 | EGFR (0.79) | EGFRCDK1SOS1 | |
| SCHEMBL5066766 | 0.79 | EGFR (0.80) | EGFRCDK1 | |
| SCHEMBL5134221 | 0.79 | EGFR (1.00) | EGFRCDK1CA1CA2 | |
| SCHEMBL14462118 | 0.78 | EGFR (0.75) | EGFRCDK1 | |
| SCHEMBL5066710 | 0.78 | EGFR (0.83) | EGFRCDK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| EP-1912639-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | ABL1, MAP3K19, PI4KB | EGFR 538/4885CDK1 56/4885DYRK1A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.